| Bioactivity | BACE1-IN-12 (compound 7g) is a potent and BBB-penetrated BACE1 inhibitor, with an IC50 of 8.9 µM. BACE1-IN-12 shows selective BuChE (butyrylcholinesterase) inhibitory activity with an IC50 of 3.2 µM. BACE1-IN-12 shows effective antioxidant effect with an IC50 of 10.2 μM (DPPH). BACE1-IN-12 might be served as a potential anti-Alzheimer agent[1]. |
| Target | IC50: 8.9 ± 0.20 µM (BACE1), 3.2 ± 0.2 µM (BuChE) |
| Name | BACE1-IN-12 |
| CAS | 2479315-19-8 |
| Formula | C29H28Cl2N6O |
| Molar Mass | 547.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Haghighijoo Z, et al. N-Cyclohexylimidazo[1,2-a]pyridine derivatives as multi-target-directed ligands for treatment of Alzheimer's disease. Bioorg Chem. 2020 Oct;103:104146. |
BACE1-IN-12
CAS: 2479315-19-8 F: C29H28Cl2N6O W: 547.48
BACE1-IN-12 (compound 7g) is a potent and BBB-penetrated BACE1 inhibitor, with an IC50 of 8.9 µM. BACE1-IN-12 shows sel
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.